ATE369846T1 - Verwendung von 1,3-propanediol derivaten - Google Patents

Verwendung von 1,3-propanediol derivaten

Info

Publication number
ATE369846T1
ATE369846T1 AT02025422T AT02025422T ATE369846T1 AT E369846 T1 ATE369846 T1 AT E369846T1 AT 02025422 T AT02025422 T AT 02025422T AT 02025422 T AT02025422 T AT 02025422T AT E369846 T1 ATE369846 T1 AT E369846T1
Authority
AT
Austria
Prior art keywords
optionally substituted
propanediol derivatives
chem
independently
compound
Prior art date
Application number
AT02025422T
Other languages
English (en)
Inventor
Sylvain Cottens
Robert Paul Hof
Roland Wenger
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE369846T1 publication Critical patent/ATE369846T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Light Receiving Elements (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02025422T 1996-11-19 1997-11-17 Verwendung von 1,3-propanediol derivaten ATE369846T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds

Publications (1)

Publication Number Publication Date
ATE369846T1 true ATE369846T1 (de) 2007-09-15

Family

ID=10803173

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02025422T ATE369846T1 (de) 1996-11-19 1997-11-17 Verwendung von 1,3-propanediol derivaten
AT97951219T ATE275947T1 (de) 1996-11-19 1997-11-17 Neue verwendung von 1,3-propanediol derivaten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97951219T ATE275947T1 (de) 1996-11-19 1997-11-17 Neue verwendung von 1,3-propanediol derivaten

Country Status (24)

Country Link
US (3) US6274629B1 (de)
EP (2) EP1312359B1 (de)
JP (2) JP4004070B2 (de)
CN (2) CN1146411C (de)
AT (2) ATE369846T1 (de)
AU (1) AU728420B2 (de)
BR (1) BR9713105A (de)
CA (1) CA2270952C (de)
CZ (1) CZ174999A3 (de)
DE (2) DE69738033T2 (de)
DK (1) DK1312359T3 (de)
ES (2) ES2289041T3 (de)
GB (1) GB9624038D0 (de)
HU (1) HUP0000343A3 (de)
ID (1) ID21568A (de)
IL (1) IL129824A (de)
NO (1) NO992259D0 (de)
NZ (1) NZ335629A (de)
PL (1) PL190348B1 (de)
PT (2) PT941082E (de)
RU (1) RU2217136C2 (de)
SI (1) SI1312359T1 (de)
SK (1) SK284806B6 (de)
WO (1) WO1998022100A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE288414T1 (de) 1998-11-11 2005-02-15 Novartis Pharma Gmbh Herstellung von 2-amino-2(2-(4- alkylphenyl)äthyl)propan-1,3-diolen
US6610718B2 (en) * 1999-12-16 2003-08-26 Teva Pharmaceutical Industries Ltd. Processes for making- and a new crystalline form of- leflunomide
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
CA2435739A1 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
DE60208180T2 (de) * 2001-04-20 2006-08-17 Debiopharm S.A. Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung
NZ529044A (en) * 2001-06-08 2008-03-28 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
RU2330839C2 (ru) 2002-01-11 2008-08-10 Санкио Компани, Лимитед Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
DE202004021680U1 (de) 2003-04-08 2010-04-22 Novartis Ag Feste pharmazeutische Zusammensetzung
EP1484057A1 (de) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Verwendung von 2-amino-1,3-propandiolderivaten zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
MXPA05014216A (es) * 2003-06-24 2006-03-13 Univ Connecticut Metodos para inhibir permeabilidad vascular y apoptosis.
US7074659B2 (en) * 2003-11-13 2006-07-11 Volterra Semiconductor Corporation Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor
TWI355934B (en) 2004-02-24 2012-01-11 Sankyo Co Pharmaceutical composition for treatment or prophy
PT1773307E (pt) * 2004-07-30 2015-01-14 Novartis Ag Formulações de compostos à base de 2-amino-1,3- propanodiol
PT1961734E (pt) * 2005-12-15 2011-10-06 Mitsubishi Tanabe Pharma Corp Composto de amina e sua utilização para fins médicos
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP6484567B2 (ja) * 2013-03-05 2019-03-13 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ ２−アミノ−１，３−プロパンジオール化合物およびその塩の製造のための方法
EA201890477A1 (ru) 2015-09-18 2018-08-31 Сановел Иладж Санайи Ве Тиджарет А.С. Инкапсулированная композиция финголимода
US20240262783A1 (en) * 2021-05-31 2024-08-08 Shanghai Bocimed Pharmaceutical Co., Ltd. Pharmaceutical salt of fingolimod, preparation method, pharmaceutical composition and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904679A (en) * 1972-05-23 1975-09-09 Upjohn Co 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
ATE327331T1 (de) * 1991-07-25 2006-06-15 Biogen Idec Inc Rekombinante antikörper zur humanen therapie
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
EP0627406B1 (de) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1, 3- propandiolverbindung und immunosuppressium
ATE279185T1 (de) 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
DE69840169D1 (de) * 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid

Also Published As

Publication number Publication date
DE69738033D1 (de) 2007-09-27
SK65999A3 (en) 1999-12-10
SI1312359T1 (sl) 2008-08-31
JP4004070B2 (ja) 2007-11-07
DE69730727D1 (de) 2004-10-21
US20010056124A1 (en) 2001-12-27
CN1146411C (zh) 2004-04-21
US20030069315A1 (en) 2003-04-10
EP1312359A3 (de) 2004-01-02
HK1022639A1 (en) 2000-08-18
ES2227726T3 (es) 2005-04-01
EP0941082B1 (de) 2004-09-15
NO992259L (no) 1999-05-10
ID21568A (id) 1999-06-24
JP2004256554A (ja) 2004-09-16
HUP0000343A3 (en) 2001-06-28
NZ335629A (en) 2001-09-28
WO1998022100A3 (en) 1998-06-25
DE69730727T2 (de) 2005-09-22
ATE275947T1 (de) 2004-10-15
WO1998022100A2 (en) 1998-05-28
SK284806B6 (sk) 2005-11-03
PT1312359E (pt) 2007-11-09
US6486209B2 (en) 2002-11-26
NO992259D0 (no) 1999-05-10
CN1293876C (zh) 2007-01-10
AU5483198A (en) 1998-06-10
CA2270952C (en) 2007-09-18
AU728420B2 (en) 2001-01-11
CZ174999A3 (cs) 1999-08-11
JP2001503780A (ja) 2001-03-21
CN1515253A (zh) 2004-07-28
DE69738033T2 (de) 2008-04-30
EP1312359B1 (de) 2007-08-15
HUP0000343A2 (hu) 2000-12-28
ES2289041T3 (es) 2008-02-01
GB9624038D0 (en) 1997-01-08
CA2270952A1 (en) 1998-05-28
US6274629B1 (en) 2001-08-14
EP0941082A2 (de) 1999-09-15
IL129824A0 (en) 2000-02-29
EP1312359A2 (de) 2003-05-21
BR9713105A (pt) 2000-04-11
IL129824A (en) 2003-07-31
CN1237906A (zh) 1999-12-08
PL333463A1 (en) 1999-12-20
RU2217136C2 (ru) 2003-11-27
PL190348B1 (pl) 2005-11-30
DK1312359T3 (da) 2007-10-08
PT941082E (pt) 2004-12-31

Similar Documents

Publication Publication Date Title
DE69738033D1 (de) Verwendung von 1,3-propanediol derivaten
ATE125539T1 (de) 1,4-benzothiazedinderivat.
ATE263771T1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
EA200100310A1 (ru) Кислородсодержащие гетероциклические соединения
ATE172463T1 (de) Pyrrolocarbazol
ES2065994T3 (es) Beta-dicetonas substituidas.
AU8813891A (en) New compounds
DK415789A (da) Tetracykliske antidepressive midler
MX170732B (es) Composicion de derivados de succinimida y su uso
FI845102L (fi) Imidazo/1,2-c/pyrimidiner.
ATE116290T1 (de) 4,5-polymethylen-4-isothiazolin-3-on-derivate mit biocider wirkung.
DK0411394T3 (da) Imidazoquinolon-derivater
DE69103985D1 (de) N-Alkylthiazolidinderivate.
ES2077697T3 (es) Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1312359

Country of ref document: EP

REN Ceased due to non-payment of the annual fee